The 36-month beta value for AMRX is at 1.05. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AMRX is 143.62M, and currently, shorts hold a 2.93% of that float. The average trading volume for AMRX on June 20, 2025 was 1.87M shares.
AMRX) stock’s latest price update
Amneal Pharmaceuticals Inc (NASDAQ: AMRX) has experienced a rise in its stock price by 0.51 compared to its previous closing price of 7.90. However, the company has seen a gain of 2.06% in its stock price over the last five trading days. zacks.com reported 2025-06-13 that Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
AMRX’s Market Performance
Amneal Pharmaceuticals Inc (AMRX) has experienced a 2.06% rise in stock performance for the past week, with a 5.87% rise in the past month, and a -9.05% drop in the past quarter. The volatility ratio for the week is 3.41%, and the volatility levels for the past 30 days are at 2.37% for AMRX. The simple moving average for the past 20 days is 5.54% for AMRX’s stock, with a -2.44% simple moving average for the past 200 days.
Analysts’ Opinion of AMRX
Many brokerage firms have already submitted their reports for AMRX stocks, with Goldman repeating the rating for AMRX by listing it as a “Buy.” The predicted price for AMRX in the upcoming period, according to Goldman is $12 based on the research report published on June 06, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see AMRX reach a price target of $12, previously predicting the price at $9. The rating they have provided for AMRX stocks is “Overweight” according to the report published on February 24th, 2025.
JP Morgan gave a rating of “Neutral” to AMRX, setting the target price at $9 in the report published on September 06th of the previous year.
AMRX Trading at 6.62% from the 50-Day Moving Average
After a stumble in the market that brought AMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMRX starting from Patel Gautam, who sale 94,906 shares at the price of $8.02 back on Jun 16 ’25. After this action, Patel Gautam now owns 1,609,144 shares of Amneal Pharmaceuticals Inc, valued at $761,146 using the latest closing price.
Patel Gautam, the Director of Amneal Pharmaceuticals Inc, sale 56,426 shares at $8.02 during a trade that took place back on Jun 10 ’25, which means that Patel Gautam is holding 1,704,050 shares at $452,537 based on the most recent closing price.
Stock Fundamentals for AMRX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.37 for the gross margin
The net margin for Amneal Pharmaceuticals Inc stands at -0.0. The total capital return value is set at 0.16. Equity return is now at value -155.38, with -0.38 for asset returns.
Based on Amneal Pharmaceuticals Inc (AMRX), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 2.54. The interest coverage ratio of the stock is 1.44.
Currently, EBITDA for the company is 439.77 million with net debt to EBITDA at 4.45. When we switch over and look at the enterprise to sales, we see a ratio of 2.2. The receivables turnover for the company is 3.54for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.40.
Conclusion
In conclusion, Amneal Pharmaceuticals Inc (AMRX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
